CD38 and cancer: The study of CD38 as a receptor started more than three decades ago and, as is true for several other cell membrane enzymes, more recently it has been refocused toward its expression and function in cancer cells, leading to the proposal of CD38 as a target for anti-cancer drugs (97–99).